Richard A. Meier

Filings by Richard A. Meier span 4 companies, the busiest being Biomarin Pharmaceutical Inc, Intersect ENT, Inc. and Accendra Health Inc/VA/. Between 5 February 2016 and 20 May 2025, the trades on record add up to 57 filings.

Market trades split into 5 purchases (€147k) and 8 sales (€1.2M). Sales outweigh purchases by €1.0M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 29 share grants and 10 option exercises.

The median purchase comes to €30k. None of the 5 purchases we analysed coincided with buying by another insider of the same company within 30 days.

The record was last updated on 22 May 2025 with a share grant in Biomarin Pharmaceutical Inc. The most recent open-market purchase was published on 17 March 2020, 2,411 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.